Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H12N2S.ClH |
Molecular Weight | 240.7538 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SMILES
c1ccc(cc1)[C@@]2([H])CN3CCSC3=N2.Cl
InChI
InChIKey=LAZPBGZRMVRFKY-HNCPQSOCSA-N
InChI=1S/C11H12N2S.ClH/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10;/h1-5,10H,6-8H2;1H/t10-;/m1./s1
Levamisole (the trade name Ergamisol), an anthelminthic drug with immunological properties. It also has antitumor activity when administered with 5-fluorouracil in patients with Duke's C colorectal carcinoma; however, this use was discontinued. The mechanism of the antitumor effect is unknown but has been postulated to be related to levamisole's immunomodulatory properties. Levamisole can stimulate antibody formation to various antigens, enhance T-cell responses by stimulating T-cell activation and proliferation, potentiate monocyte and macrophage functions including phagocytosis, chemotaxis and increases motility, adherence, and chemotaxis. Levamisole inhibits alkaline phosphatase and possesses cholinergic activity. The mechanism of action of levamisole as an antiparasitic agent, for example, to treat ascariasis, relates to its agonistic activity to L-subtype nicotinic acetylcholine receptors in nematode muscles. In addition, levamisole was studied for preventing relapses of the steroid-sensitive idiopathic nephrotic syndrome (SSINS). It was shown, that alone or in combination with steroids, the drug can prolong the time to relapse and prevented recurrence during one year of treatment. However, these studies also were also discontinued.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P05186|||Q5BKZ5
Gene ID: 249.0
Gene Symbol: ALPL
Target Organism: Homo sapiens (Human)
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28209522
|
|||
Target ID: CHEMBL1884
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19668355
|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative |
ERGAMISOL
Approved UseUnknown
Launch Date6.4558078E11
|
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6995094
|
Curative |
Unknown
Approved UseUnknown
|
||
Preventing |
Unknown
Approved UseUnknown
|
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.76 mg/L
|
150 mg unknown, oral
dose: 150 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.93 mg/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
5 mg/kg bw single, oral
dose: 5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
1.53 mg/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
5 mg/kg bw single, oral
dose: 5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.84 mg/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
5 mg/kg bw single, oral
dose: 5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
0.72 mg/L
|
150 mg unknown, oral
dose: 150 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.75 mg/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.74 mg/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
1.28 mg/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
5 mg/kg bw single, oral
dose: 5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.97 mg/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
0.69 mg/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.53 mg/L
|
2.5 mg/kg bw 1 times / 2 days multiple, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.15 mg × h/L
|
150 mg unknown, oral
dose: 150 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
13.78 mg × h/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
5 mg/kg bw single, oral
dose: 5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
18.96 mg × h/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
5 mg/kg bw single, oral
dose: 5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
19.69 mg × h/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
5 mg/kg bw single, oral
dose: 5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
3.07 mg × h/L
|
150 mg unknown, oral
dose: 150 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.48 mg × h/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.1 mg × h/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
6.88 mg × h/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
5 mg/kg bw single, oral
dose: 5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7.16 mg × h/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
7.44 mg × h/L
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.54 mg × h/L
|
2.5 mg/kg bw 1 times / 2 days multiple, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.4 h
|
150 mg unknown, oral
dose: 150 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
3.65 h
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
5 mg/kg bw single, oral
dose: 5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
5.75 h
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
5 mg/kg bw single, oral
dose: 5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.58 h
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
5 mg/kg bw single, oral
dose: 5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
5.56 h
|
150 mg unknown, oral
dose: 150 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.85 h
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.88 h
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
2.71 h
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
5 mg/kg bw single, oral
dose: 5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.72 h
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
6.04 h
EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166176/
|
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.07 h
|
2.5 mg/kg bw 1 times / 2 days multiple, oral
dose: 2.5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
49%
|
150 mg unknown, oral
dose: 150 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
49%
|
150 mg unknown, oral
dose: 150 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
LEVAMISOLE plasma |
Homo sapiens
population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg 2 times / day multiple, oral
Dose: 50 mg, 2 times / day Route: oral Route: multiple Dose: 50 mg, 2 times / day Sources: |
unhealthy, 15 years
n = 1 Health Status: unhealthy Age Group: 15 years Sex: M Population Size: 1 Sources: |
Disc. AE: Epidermal necrolysis...
AEs leading to discontinuation/dose reduction: Epidermal necrolysis (1 patient) Sources:
|
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: |
unhealthy, 34 years
n = 1 Health Status: unhealthy Age Group: 34 years Sex: F Population Size: 1 Sources: |
Disc. AE: Myopathy, Leukocytoclastic vasculitis...
AEs leading to discontinuation/dose reduction: Myopathy (1 patient) Sources:
Leukocytoclastic vasculitis (1 patient) |
250 mg single, intravenous
Overdose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: |
unknown, 52 years
n = 1 Health Status: unknown Age Group: 52 years Sex: M Population Size: 1 Sources: |
Other AEs: Adverse event...
|
3.5 mg/kg 1 times / day multiple, oral
Highest studied dose Dose: 3.5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 3.5 mg/kg, 1 times / day Sources: |
unhealthy, 7-12 years
n = 28 Health Status: unhealthy Condition: pediculosis capitis Age Group: 7-12 years Sex: F Population Size: 28 Sources: |
|
150 mg 1 times / week multiple, oral
Dose: 150 mg, 1 times / week Route: oral Route: multiple Dose: 150 mg, 1 times / week Sources: |
unhealthy
Health Status: unhealthy Sources: |
Disc. AE: Agranulocytosis...
AEs leading to discontinuation/dose reduction: Agranulocytosis Sources:
|
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Epidermal necrolysis | 1 patient Disc. AE |
50 mg 2 times / day multiple, oral
Dose: 50 mg, 2 times / day Route: oral Route: multiple Dose: 50 mg, 2 times / day Sources: |
unhealthy, 15 years
n = 1 Health Status: unhealthy Age Group: 15 years Sex: M Population Size: 1 Sources: |
Leukocytoclastic vasculitis | 1 patient Disc. AE |
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: |
unhealthy, 34 years
n = 1 Health Status: unhealthy Age Group: 34 years Sex: F Population Size: 1 Sources: |
Myopathy | 1 patient Disc. AE |
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: |
unhealthy, 34 years
n = 1 Health Status: unhealthy Age Group: 34 years Sex: F Population Size: 1 Sources: |
Adverse event | grade 5 |
250 mg single, intravenous
Overdose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: |
unknown, 52 years
n = 1 Health Status: unknown Age Group: 52 years Sex: M Population Size: 1 Sources: |
Agranulocytosis | Disc. AE |
150 mg 1 times / week multiple, oral
Dose: 150 mg, 1 times / week Route: oral Route: multiple Dose: 150 mg, 1 times / week Sources: |
unhealthy
Health Status: unhealthy Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Tumour necrosis factor-alpha production in fibrosing alveolitis is macrophage subset specific. | 2001 |
|
Non-corticosteroid treatment for nephrotic syndrome in children. | 2001 |
|
Optimising the benefits of anthelmintic treatment in children. | 2001 |
|
[Clinical and immunological characteristics and specific features of the treatment of patients with recurrent sarcoidosis of respiratory organs]. | 2001 |
|
Oral bioavailability of levamisole in goats. | 2001 Dec |
|
Effects of anthelmintics on the development of eggs of Angiostrongylus costaricensis in vitro. | 2001 Dec |
|
Prevalence of anthelmintic resistance in gastrointestinal nematodes of dairy goats under extensive management conditions in southwestern France. | 2001 Dec |
|
Determination of levamisole in animal tissues using liquid chromatography with ultraviolet detection. | 2001 Dec |
|
Prospective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma. | 2001 Dec |
|
Regulation of distinct muscle behaviors controls the C. elegans male's copulatory spicules during mating. | 2001 Dec 14 |
|
Multiple anthelmintic resistance in sheep. | 2001 Dec 22-29 |
|
Partial purification and biochemical characterization of a heteromeric protein phosphatase 2A holoenzyme from maize (Zea mays L.) leaves that dephosphorylates C4 phosophoenolpyruvate carboxylase. | 2001 Jul |
|
Cimetidine and levamisole versus cimetidine alone for recalcitrant warts in children. | 2001 Jul-Aug |
|
Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. | 2001 Nov 16 |
|
Adjuvant chemotherapy for colorectal cancer. | 2001 Nov 16 |
|
Oxidative modification of rat liver 5'-nucleotidase: the mechanisms for protection and re-activation. | 2001 Oct |
|
Levamisole vs. cyclophosphamide for frequently-relapsing steroid-dependent nephrotic syndrome. | 2001 Oct |
|
Levamisole and/or Chinese medicinal herbs can modulate the serum level of squamous cell carcinoma associated antigen in patients with erosive oral lichen planus. | 2001 Oct |
|
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. | 2001 Oct 11 |
|
An in vivo evaluation of induction of abnormal sperm morphology by some anthelmintic drugs in mice. | 2001 Oct 18 |
|
Alkaline phosphatase from rat liver and kidney is differentially modulated. | 2001 Sep |
|
Are Teladorsagia circumcincta (Nematoda) morphs equally able to survive under anthelmintic treatment in sheep on pastures? | 2001 Sep |
|
Response shift in the perception of health for utility evaluation. an explorative investigation. | 2001 Sep |
|
Genetic variability following selection of Haemonchus contortus with anthelmintics. | 2001 Sep |
|
Population genetics and drug resistance in nematode. | 2001 Sep |
|
[Treatment of dystrophy, dysplasia and initial stages of vulvar carcinoma in virus infections]. | 2002 |
|
Kinetic comparison of tissue non-specific and placental human alkaline phosphatases expressed in baculovirus infected cells: application to screening for Down's syndrome. | 2002 |
|
Modulation of insulin transport in rat brain microvessel endothelial cells by an ecto-phosphatase activity. | 2002 |
|
Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center. | 2002 Apr 1 |
|
Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. | 2002 Apr 1 |
|
Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. | 2002 Apr 1 |
|
A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. | 2002 Apr 22 |
|
213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. | 2002 Apr 8 |
|
Effect in vitro of cyclic nucleotides-elevating agents on nitric oxide production by human granulocytes from type 2-diabetic patients. | 2002 Feb |
|
Role of a novel soluble nucleotide phospho-hydrolase from sheep plasma in inhibition of platelet reactivity: hemostasis, thrombosis, and vascular biology. | 2002 Feb |
|
A novel role of alkaline phosphatase in protection from immunological liver injury in mice. | 2002 Feb |
|
Modulation by levamisole of CD45RA and CD45RC isoforms expression in the gut of weaned pigs vaccinated against colibacillosis. | 2002 Feb |
|
Characterization and cytochemical localization of an ATP diphosphohydrolase from Leishmania amazonensis promastigotes. | 2002 Feb |
|
S100A4 (p9Ka) protein in colon carcinoma and liver metastases: association with carcinoma cells and T-lymphocytes. | 2002 Feb 1 |
|
A boy with cutaneous necrosis occurring during treatment with levamisole. | 2002 Jan |
|
Influence of some substances on bacterial translocation in the rat. | 2002 Jan |
|
The effect of dietary immunomodulation upon Edwardsiella tarda vaccination in healthy and immunocompromised Indian major carp (Labeo rohita). | 2002 Jan |
|
Canine serum alkaline phosphatase isoenzymes detected by polyacrylamide gel disk electrophoresis. | 2002 Jan |
|
Prevalence of levamisole and benzimidazole resistance in oesophagostomum populations of pig-breeding farms in North Rhine-Westphalia, Germany. | 2002 Jan |
|
Unique Ca(2+)-activated ATPase in the nervous ganglia of Phyllocaulis soleiformis (Mollusca). | 2002 Jan |
|
Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix. | 2002 Jan 21 |
|
Necessity of enzymatic activity of alkaline phosphatase for mineralization of osteoblastic cells. | 2002 Mar |
|
Inhibitor profiles of alkaline phosphatases in bovine preattachment embryos and adult tissues. | 2002 Mar |
|
The C. elegans ric-3 gene is required for maturation of nicotinic acetylcholine receptors. | 2002 Mar 1 |
|
Superantigen reactive Vbeta6+ T cells induce perforin/granzyme B mediated caspase-independent apoptosis in tumour cells. | 2002 Mar 4 |
Sample Use Guides
In Vivo Use Guide
Sources: http://home.intekom.com/pharm/janssen/ergamis.html
The combination of ERGAMISOL (levamisole hydrochloride) and 5-fluorouracil is administered according to the following dosage schedule:
Initial Therapy: Week 1 (3rd to 4th week post surgery): 5-fluorouracil 450 mg/m² i.v. push days 1 –5 and ERGAMISOL 50 mg orally t.i.d days 1 –3; Week 3 only ERGAMISOL 50 mg orally t.i.d days 1 –3. Therapy should commence 3 –4 weeks post surgery.
5-Fluorouracil (450 mg/m²) is administered by rapid i.v. injection for the first 5 days of Week 1.
ERGAMISOL 50 mg tablet is administered orally three times a day for the first 3 days of Week 1, and again on the first 3 days of Week 3.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1790137
It was examined the immunological effects of levamisole in vitro. Experiments utilized peripheral blood mononuclear cells from normal donors incubated in the presence of increasing concentrations of levamisole (0.1 to 100 micrograms/ml). Levamisole had no consistent effect on induction of 2',5'-oligoadenylate synthetase activity or indoleamine-2,3-dioxygenase activity, or production of tumor necrosis factor. Levamisole had no effect on monocyte cytotoxicity or expression of HLA-DR, HLA-DQ, HLA-DP, and the Fc receptor. Similarly, levamisole had no significant effect on NK or LAK cytotoxicity or the immunological activation of T-lymphocytes, assessed by expression of CD3, CD4, CD8, CD16, CD25, and CD56. No significant enhancement in the expression of three tumor-associated antigens (880364, NRCO-4, and ING-1) and the intercellular adhesion molecule-1 (ICAM-1) antigen on four human cancer cell lines was observed following in vitro exposure to levamisole. In conclusion, was revealed, that levamisole was not a potent modulator of the immune parameters.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/05/324
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
||
|
CFR |
21 CFR 520.1242E
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
||
|
NCI_THESAURUS |
C2141
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
||
|
CFR |
21 CFR 556.350
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
16595-80-5
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
PRIMARY | |||
|
DBSALT000822
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
PRIMARY | |||
|
C610
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
PRIMARY | |||
|
LEVAMISOLE HYDROCHLORIDE
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
PRIMARY | Description: A white or almost white, crystalline powder. Solubility: Freely soluble in water; soluble in ethanol (~750 g/L) TS; slightly soluble in dichloromethane R. Category: Anthelminthic. Storage: Levamisole hydrochloride should be kept in a well-closed container, protected from light. Requirement: Levamisole hydrochloride contains not less than 98.5% and not more than 101.0% of C11H12N2S,HCl, calculated with reference to the dried substance. | ||
|
16595-80-5
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
PRIMARY | |||
|
CHEMBL1454
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
PRIMARY | |||
|
DL9055K809
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
PRIMARY | |||
|
27944
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
PRIMARY | |||
|
SUB02902MIG
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
PRIMARY | |||
|
1359302
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
PRIMARY | USP-RS | ||
|
M6781
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
PRIMARY | Merck Index | ||
|
227227
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
PRIMARY | RxNorm | ||
|
240-654-6
Created by
admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD